St Barbara rallies as gold sector comes under pressure

Published 20-JAN-2017 13:13 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

As the S&P/ASX 200 gold index (XGD) shed 2% on the back of a decline in the gold price, shares in multi-mine gold producer, St Barbara (ASX: SBM) rallied more than 2%, perhaps spurred on by a positive review of the company’s operations by analysts at Macquarie.

The broker was impressed with the group’s performance from its Gwalia and Simberi gold projects where December quarter production of circa 70,900 ounces and 28,000 ounces respectively compared favourably with the broker’s estimates of 63,900 ounces and 23,000 ounces.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

The Gwalia mine is in Western Australia, while Simberi is located in New Ireland, Papua New Guinea.

In providing its quarterly update St Barbara lifted the lower end of its full-year production guidance for Gwalia by 10,000 ounces to 255,000 ounces, and the group is expecting annual production from Simberi to be in a range between 95,000 ounces and 105,000 ounces.

Macquarie’s production forecasts at top end of guidance

Macquarie’s production forecasts for fiscal 2017 sits at the top end of guidance with the broker’s projections based on combined output of 364,700 ounces.

Apart from the exceeding Macquarie’s production guidance, the broker also said that the company had outperformed on the costs front with Simberi approximately 10% below expectations.

This prompted the broker to upgrade its fiscal 2017 earnings forecast by 6%, resulting in a 12% increase in its price target which now stands at $2.90 per share.

This implies further upside from Thursday’s high of $2.41. However, Macquarie also sees St Barbara as a possible takeover target, or perhaps a suitor given it is expected to generate annual free cash flow in a range between $150 million and $200 million over the next five years.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X